GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) touted data today from a non-inferiority lung function study evaluating its inhaled, once-daily corticosteroid/long-acting beta2 agonist combination therapy in patients with asthma.
The study showed that patients with well-controlled asthma could switch from the twice-daily Seretide Accuhaler to the companies’ once-daily Relvar Ellipta therapy without compromising lung function.
Get the full story at our sister site, Drug Delivery Business News.